Understand the respiratory partnering landscape using intelligence from 464 real-world collaboration and licensing deals.
Respiratory Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 464 partnering deals involving respiratory assets, technologies and development programs.
Respiratory partnering spans a diverse range of acute and chronic conditions, with transaction structures reflecting established treatment approaches alongside innovation in biologics, inhaled therapies, targeted treatments and emerging technologies.
The report brings this activity together in one resource, enabling users to understand who is partnering, which respiratory opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in respiratory partnering.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad respiratory benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Identify comparable respiratory transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking respiratory opportunities across relevant indications, technologies, targets and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable respiratory assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building respiratory portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
The briefing applies the underlying respiratory deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Respiratory Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 464 partnering deals involving respiratory assets, technologies and development programs.
Respiratory partnering spans a diverse range of acute and chronic conditions, with transaction structures reflecting established treatment approaches alongside innovation in biologics, inhaled therapies, targeted treatments and emerging technologies.
The report brings this activity together in one resource, enabling users to understand who is partnering, which respiratory opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in respiratory partnering.
Understand the respiratory partnering landscape
The report analyzes respiratory dealmaking from 2016 to 2026, including:
- Trends in respiratory partnering by year
- Deal activity by deal type
- Industry sector
- Stage of development at the time of partnering
- Technology type
- Therapeutic indication
- Most active respiratory dealmakers
- Leading deals by disclosed value
- How respiratory partnering activity is evolving
Benchmark respiratory deal financials
Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.The report provides dedicated analysis of disclosed financial terms, including:
- Headline deal values
- Upfront payments
- Milestone payments
- Royalty rates
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading respiratory dealmakers and prospective partners
The report identifies the most active companies in respiratory partnering and provides transaction histories that enable users to investigate their previous activity.This can help users identify:
- Companies actively seeking respiratory opportunities
- Prospective licensing and collaboration partners
- Organizations repeatedly partnering in relevant respiratory indications
- Companies active at relevant stages of development
- Dealmakers demonstrating interest in particular technologies, modalities or therapeutic approaches
- Competitors pursuing related external innovation strategies
Compare partnering activity across respiratory indications and targets
Respiratory disease encompasses a range of acute and chronic conditions, biological targets and treatment approaches with differing scientific, clinical and commercial dynamics.The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad respiratory benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Understand how respiratory agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.Depending on the transaction and available disclosure, users can investigate areas including:
- Rights granted and retained
- Research and development responsibilities
- Licensing rights
- Exclusivity
- Geographic rights
- Intellectual property
- Development and regulatory obligations
- Manufacturing and supply responsibilities
- Commercialization rights
- Financial consideration
- Milestones and royalties
- Governance
- Term and termination provisions
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected respiratory transactions.These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:
- Scope of rights
- Development obligations
- Intellectual property
- Exclusivity
- Financial terms
- Milestone triggers
- Royalty provisions
- Commercialization rights
- Termination and other negotiated provisions
Comprehensive respiratory deal directory
The report includes a comprehensive directory of 464 respiratory collaboration and licensing deals, providing a focused resource for identifying relevant precedent transactions.Deals can be reviewed by:
- Company
- Technology type
- Therapeutic indication or target
- Contract availability
Who should use this report?
Business Development and Licensing teamsIdentify comparable respiratory transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking respiratory opportunities across relevant indications, technologies, targets and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable respiratory assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building respiratory portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide respiratory intelligence into company-specific insight
For qualifying customers, the analyst can also provide a Customized Executive Partnering Briefing alongside the report.The briefing applies the underlying respiratory deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in respiratory dealmaking
Chapter 3 - Financial deal terms for respiratory partnering
Chapter 4 - Leading respiratory deals and dealmakers
Chapter 5 - Respiratory contract document directory
Chapter 6 - Respiratory dealmaking by therapeutic target
Deal directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3M
- 4D Molecular Therapeutics
- 4D Pharma
- AazeinTx
- Abbott Laboratories
- Abbvie
- Abingworth Life Sciences
- Abionic
- ABVC BioPharma
- Acceleron Pharma
- Aclaris Therapeutics
- Acrobat Genomics
- Actelion
- AdAlta
- Adalvo
- Adamis Pharmaceuticals
- adMare BioInnovations
- ADM Tronics
- Advanced Biological Laboratories
- Advanz Pharma
- Advent Therapeutics
- Aerami Therapeutics
- Aerogen
- AeroRx Therapeutics
- Aerpio Pharmaceuticals
- Affibody
- AGC Biologics
- AgeX Therapeutics
- Aidoc
- AirNexis Therapeutics
- AIT Therapeutics
- Akari Therapeutics
- Akonni Biosystems
- Albany Molecular Research
- Alex Therapeutics
- Allakos
- Allegheny Technologies
- Allinaire Therapeutic
- Alpine Immune Sciences
- Altavant Sciences
- Altum Pharmaceuticals
- Aluna
- Alveolus
- Alvotech
- American Association for Laboratory Accreditation
- American College of Chest Physicians
- American Lung Association
- Amneal Pharmaceuticals
- AMO Pharma
- Amyndas Pharmaceuticals
- Analytics 4 Life
- AnGes MG
- Anthem
- Anthem Bluecross
- Apple
- Aptar Pharma
- Aptuit
- Arch Biopartners
- Arcturus Therapeutics
- Arena Pharmaceuticals
- Aridis Pharmaceuticals
- Aristea Therapeutics
- Ark Biosciences
- Arrowhead Pharmaceuticals
- ARS Pharmaceuticals
- ArtiQ
- ARUP Laboratories
- Aslan Pharma
- AssisTek
- Asthma UK
- AstraZeneca
- Athersys
- Atrapos Therapeutics
- aTyr Pharma
- Avicenna Technology
- Avrobio
- AzarGen Biotechnologies
- Bausch Health Companies
- Bayer
- Baylor Health Care System
- Beijing Tide Pharmaceutical
- Ben-Gurion University
- BenevolentAI
- Be The Match BioTherapies
- Beth Israel Deaconess Medical Center
- BetterLife Pharma
- Beyond Air
- Bicycle Therapeutics
- Bill and Melinda Gates Foundation
- Bio-Me
- Bio-Techne
- BioAegis Therapeutics
- bioAffinity Technologies
- Bioforum
- BioKey
- BioLink Life Sciences
- Biolojic Design
- BioLum Sciences
- Biomedical Advanced Research and Development Authority
- BiomEdit
- BioMed X Innovation Center
- Biophytis
- BiosanaPharma
- Biosion
- BioVersys
- Blanver
- Blu Biotech
- Blue Cross Blue Shield Association
- Blue Shield of California
- BNC Korea
- Boehringer Ingelheim
- Bonne Santé Group
- Boomer Esiason Foundation
- Bora Pharmaceuticals
- Boston Scientific
- Boston University School of Medicine
- Brainomix
- Breath Therapeutics
- Bridge Biotherapeutics
- Brigham and Women's Hospital
- BrightInsight
- Bristol-Myers Squibb
- British Lung Foundation
- Broncus Technologies
- Brown University
- C4X Discovery
- California Institute for Biomedical Research
- California Institute for Regenerative Medicine
- Cambridge Healthcare Innovations
- Canadian Blood Services
- Cannex Scientific
- Cantex Pharmaceuticals
- CARB-X
- Cardiovascular Systems
- Carnegie Mellon University
- Cedars-Sinai Medical Center
- Celgene
- Cellect Biotechnology
- CELLINK
- Cellix Bio
- Celltrion
- Celularity
- Charak Foundation
- Charite Universitatsmedizin Berlin
- Chiesi Farmaceutici
- Children's Hospital Boston
- China Medical System
- Chronolife
- Cilag AG
- Cincinnati Children’s Hospital Medical Center
- Cipla
- Circassia
- Citius Pharmaceuticals
- Clalit Health Services
- Clario
- CN Bio
- Coalition for Epidemic Preparedness Innovations
- Coeptis Therapeutics
- CohBar
- Collplant
- Combioxin
- Commense
- Commonwealth of Pennsylvania
- CompleWare
- Context Therapeutics
- COPD Foundation
- Corsair Pharma
- Cosmo Pharmaceuticals
- CosmosID
- Covalon Technologies
- COVIRIX Medical
- CRS Bio
- CrystecPharma
- CSL
- CSL Behring
- CS Pharmaceuticals
- Cue Health
- Curadev Pharma
- Curetis
- CureVac
- CVD Equipment
- CytoReason
- Cytovation
- Daewoong Pharmaceutical
- Dalton Pharma Services
- Department of Defense
- Dermira
- Deverra Therapeutics
- DevPro Biopharma
- Diffusion Pharmaceuticals
- Diomics
- Donnelley Financial Solutions
- Dr. Reddy's Laboratories
- DSG
- Duke Clinical Research Institute (DCRI)
- Duke University
- Dymax
- Eagle Pharmaceuticals
- Edesa Biotech
- Eisai
- Eli Lilly
- Empatica
- Empirico
- ENA Respiratory
- Endpoint Health
- Enzyvant Science
- Epistemic AI
- Erasmus University Medical Center
- Essential Pharmaceuticals
- Ethris
- European Union
- Everest Medicines
- EvolveImmune Therapeutics
- Evommune
- Evotec
- Experimental Therapeutics Centre of Singapore
- Fannin
- Faron Pharmaceuticals
- Fibrocor Therapeutics
- FibroGenesis
- Flagship Pioneering
- Florica Therapeutics
- Fluidda
- fluidIQ
- Food and Drug Administration (FDA)
- Foresee Pharmaceuticals
- Forge Therapeutics
- Foundation for Sarcoidosis Research
- Fred Hutchinson Cancer Research Center
- Fujifilm Diosynth Biotechnologies
- FUJIFILM SonoSite
- Fulcrum Therapeutics
- Fusion Genomics
- Galapagos
- Gatehouse Bio
- Geisinger Health System
- GEn1E Lifesciences
- Genentech
- Genomadix
- GenScript ProBio
- Genten Therapeutics
- German Government
- Getz Healthcare
- Gilead Sciences
- Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals S.A.
- Global Coalition for Adaptive Research
- GlobalLogic
- Gossamer Bio
- Government of Canada
- Government of Israel
- GPCR Therapeutics
- Graviton Bioscience
- Green Park Collaborative
- GRI Bio
- Grifols
- GSK
- Guangzhou Institute of Respiratory Disease
- Hackensack Meridian Health
- Haisco Pharmaceutical
- Hangzhou Chance Pharmaceuticals
- Haplogen
- Harbour Biomed
- Harvard Stem Cell Institute
- Harvard University
- Harvest Capital Strategies
- HCmed Innovations
- Healios K.K.
- Healium Medical
- Health Care Originals
- HealthPrize Technologies
- HealthSnap
- HealthTrust Purchasing Group
- Hebrew University of Jerusalem
- Helix
- Hemovent
- Henry M. Jackson Foundation
- Highmark Health
- Hikma Pharmaceuticals
- Honeywell
- Hong Kong Polytechnic University
- Hoth Therapeutics
- Humanetics
- Hyfe
- i2c Pharmaceutical Services
- iBio
- IBM
- Icagen
- Iconovo
- IDbyDNA
- IDT Biologika
- Illumina
- Imbio
- Immune Therapeutics
- Imperial College London
- Inari Medical
- Incyte
- Industrial Technology Research Institute
- Inhalation Sciences
- Inhalon Biopharma
- Inhibrx
- Innovare
- Innovate UK
- Innova Vascular
- Innoviva Specialty Therapeutics
- Innovus Pharmaceuticals
- Inovalon
- Inovio Pharmaceuticals
- Inovytec
- Insmed Inc
- Inspira Technologies
- Instem
- Institut Kanser Negara
- Integrated Computer Solutions
- Intrexon
- Inventiva
- InVixa
- Itamar Medical
- Janssen Pharmaceuticals
- Janssen Research & Development
- Janssen Sciences
- Jemincare
- JHL Biotech
- Jiangsu Hengrui Pharmaceuticals
- Jiangsu QYuns Therapeutics
- Jikei University
- Johannes Gutenberg University
- Johns Hopkins University
- Johnson & Johnson Innovation
- Kaleido Biosciences
- Kamada
- KangWon University Institute of Medical Science
- KARE Biosciences
- Karolinska Institute
- Kashiv BioSciences
- Kelun-Biotech Biopharmaceutical
- Kennedy Institute of Rheumatology
- Keyence
- Kindeva Drug Delivery
- King's College Hospital
- Knopp Biosciences
- Koye Pharmaceuticals
- Kyorin Pharmaceutical
- La Jolla Institute for Allergy & Immunology
- Lassen Therapeutics
- Launch Therapeutics
- Laurel Venture Capital
- Leading BioSciences
- Lee's Pharmaceutical
- Leidos
- LEO Pharma
- LianBio
- LifeArc
- Ligand Pharmaceuticals
- Light Chain Bioscience
- LightDeck Therapeutics
- Lipigon Pharmaceuticals
- Locus Biosciences
- Lotus Pharmaceuticals
- Lumen Biomedical
- Luminex
- LuminUltra
- Lundquist Institute
- Lung Biotechnology
- Lung Therapeutics
- Lung Transplant Foundation
- Lurie Children's Hospital of Chicago
- Lyomark Pharma
- Lyra Therapeutics
- mAbXience
- Macau University of Science and Technology
- Mallinckrodt Pharmaceuticals
- MannKind Biopharmaceuticals
- Marinomed Biotechnologie
- Marpai
- Massachusetts General Hospital
- Matrix Biomed
- Max Biopharma
- Mayo Clinic
- Medela
- Mediar Therapeutics
- Medical International Research
- Medical Technology Enterprise Consortium
- Medicines Discovery Catapult
- MediciNova
- Medicom
- MedImmune
- MediPines
- Meissa Vaccines
- Meitheal Pharmaceuticals
- Melinta Therapeutics
- Melior Pharmaceuticals
- Menarini
- Menarini Asia-Pacific
- Merck and Co
- Mereo BioPharma
- Mesoblast
- Metaba
- Methapharm
- Microbio Shanghai
- Moderna
- Momenta Pharmaceuticals
- Monopar Therapeutics
- Morphic Therapeutic
- Mount Sinai Health System
- MS Pharma
- Mundipharma
- Mylan Pharmaceuticals
- Myovant Sciences
- Nanjing King-friend Biochemical Pharmaceutical
- Nano-X Imaging
- Nanopharm
- NanoString Technologies
- NantKwest
- Nanyang Technological University
- Nashville Biosciences
- National Healthcare Services (NHS)
- National Health Service
- National Heart
- Lung and Blood Institute
- National Institute for Environmental Health Sciences
- National Institute for Health and Care Research Respiratory Translational Research Collaboration
- National Institute of Allergy and Infectious Diseases
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institutes of Health
- National Jewish Health
- National Kidney Foundation
- National Organization for Rare Disorders
- National Research Council Canada
- National Science Foundation
- Nepean Blue Mountains Local Health District’s Nepean Hospital
- Nephron Pharmaceuticals
- NeuCen BioMed
- Neurocare Group
- NeurOp
- NeuroRx
- Nexel
- NitricGen
- Nitto Denko
- North Carolina State University
- NorthStar Medical Radioisotopes
- Northwestern University
- Novartis
- NoveCite
- Novellus Therapeutics
- NRx Pharmaceuticals
- NTC
- Nuance Pharma
- Numedicus
- NuMedii
- NuvoAir
- Oak Hill Bio
- ObvioHealth
- Olympus Respiratory America
- Omdana Therapeutics
- Oneness Biotech
- Onymos
- OpGen
- Organicell Regenerative Medicine
- Orgenesis
- Orion
- Oslo University Hospital
- Owkin
- Owlstone Medical
- Palisade Bio
- Pall Corporation
- Pangaea Data
- Pantherics
- Paragonix Technologies
- Paratek Pharmaceuticals
- PARI Pharma
- Partner Therapeutics
- Patara Pharma
- Patient-Centered Outcomes Research Institute
- Peking University
- Penumbra
- Perrigo
- Pharmbio Korea
- PhaseBio Pharmaceuticals
- Philips
- Pictor
- Pieris Pharmaceuticals
- Pluristem Therapeutics
- Polarean Imaging
- Polyphor
- Precision Image Analysis
- Premier Inc
- Prenosis
- Primevera Therapeutics
- Propeller Health
- ProQR Therapeutics
- Protalix BioTherapeutics
- Provista Diagnostics
- Pulmatrix
- Pulmodyne
- Pulmonary Fibrosis Foundation (PFF)
- Pulmonomy
- PulmoSIM Therapeutics
- Pulmotree Medical
- Pulthera
- Punjab Province
- PureTech Health
- Qnovia
- QOL Devices
- Quartesian Clinical Research
- Quebec Government
- Quercis Pharma
- R4D Biotech
- Rabin Medical Center (Beilinson Hospital)
- RapidAI
- RAPT Therapeutics
- ReAlta Life Sciences
- Recipharm
- Recludix Pharma
- Recurrent Respiratory Papillomatosis Foundation
- RedHill Biopharma
- Redox
- Redx Pharma
- Relation Therapeutics
- Renovion
- Resilient Biotics
- RespirAI Medical
- Respira Therapeutics
- RespiraWorks
- RespireRx Pharmaceuticals
- resTORbio
- Revon Systems
- RION
- Roche
- Roivant Sciences
- Royal Philips Electronics
- RS BioTherapeutics
- Rubedo Life Sciences
- RxCap
- Samumed
- Sandoz
- Sanofi
- Santhera Pharmaceuticals
- SarcoMed USA
- Sarepta Therapeutics
- Savana
- Savara Pharma
- Scholar Rock
- Science 37
- Scleroderma Research Foundation
- Second Genome
- Seelos Therapeutics
- Sema4
- Sensible Medical Innovations
- Sentynl Therapeutics
- SenzaGen
- Seqirus
- Seqster
- Serna Bio
- Serum Institute of India
- Seyltx
- Shandong Luoxin Pharma
- Shaperon
- Sheba Medical Center
- Shenzhen Institutes of Advanced Technology
- Siemens Healthineers
- Silence Therapeutics
- Simulations Plus
- Sino Biopharmaceutical
- Siolta Therapeutics
- SiteOne Therapeutics
- Sleepiz
- Sonde Health
- Sonmol
- Sosei Heptares
- SpeeDx
- Spesana
- Spire Health
- SQI Diagnostics
- Stanford University School of Medicine
- Statera Biopharma
- Stemedica Cell Technologies
- Stevanato
- Stimit
- Strados Labs
- Sumitomo Dainippon Pharma
- Sumitovant Biopharma
- Sunnybrook Research Institute
- Sunovion Pharmaceuticals
- SUNY Upstate Medical University
- Surrozen
- Sutter Health
- Suzhou Intragrand Pharma
- Synergie Lyon Cancer
- Synthonics
- Taiba
- Taiho
- Takeda Pharmaceutical
- TARGET PharmaSolutions
- TB Alliance
- TCGFB
- Tektronix Component Solutions
- Teleflex
- Telesair
- TeraRecon
- Tetra Bio-Pharma
- Teva Pharmaceutical Industries
- Texas Lung Injury Institute
- TFF Pharmaceuticals
- TFS International
- The Alfred Hospital
- Therma Bright
- Thermo Fisher Scientific
- Third Pole Therapeutics
- Three Lakes Foundation
- TiGenix
- Tivic Health Systems
- TMM Software
- toSense
- Translate Bio
- Transpire
- Transpire Bio
- Trevena
- TrialSpark
- TSI Healthcare
- UCB
- United Therapeutics
- University of California
- Davis
- University of California
- San Diego
- University of California San Francisco
- University of Chicago
- University of Colorado
- University of Dundee
- University of Florida
- University of Georgia
- University of Houston
- University of Manchester
- University of Maryland Baltimore
- University of Melbourne
- University of Michigan
- University of Montana
- University of Munster
- University of Oklahoma
- University of Oxford
- University of Pennsylvania
- University of Pittsburgh
- University of Pittsburgh Medical Center
- University of Sheffield
- University of Texas at El Paso
- University of Texas Health Science Center at Tyler
- University of Virginia
- University of Wisconsin
- Urovant Sciences
- US Army
- US Army Medical Research and Material Command
- US Army Medical Research Institute of Chemical Defense
- Utrecht University
- UWM Research Foundation
- Vanderbilt University
- Vapotherm
- Variant Bio
- Vasomune Therapeutics
- Vectura
- Veeva Systems
- VenatoRx
- Veracyte
- Verantos
- Verily
- Verona Pharma
- Vicore Pharma
- Vida Diagnostics
- Virginia Catalyst
- Visby Medical
- Vituity
- Viz.ai
- Vocalis Health
- Vortran Medical
- Watchmaker Genomics
- WaVe Lifesciences
- Weill Cornell Medical College
- Windtree Therapeutics
- Windward Bio
- Wuxi STA
- Wyss Institute
- Xerox
- XL-Protein
- Xvivo Perfusion
- Xylyx Bio
- Yale School of Medicine
- Yale University
- Yissum Research Development
- YPrime
- ZappRx
- Zentiva
- ZEPHYRx
- Zymedi
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
